Ed Silverman, for STAT, reports on the continuing struggles of state governments to reign in pharmaceutical costs in the wake of the failed efforts in California. “Nearly a dozen state legislatures around the country have introduced bills that would either require drug makers to justify their pricing or provide detailed information on their costs in hopes that such transparency would slow rising prices.”
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.